Vertex Pharmaceuticals UBS Global Biopharma Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, everyone. Thank you. Michael Yee, Global Head of Biotechnology here at UBS, Senior Biotechnology Analyst. Very excited to have members of the team of Vertex Pharmaceuticals up here with us. Members of the IR team, Susie Lisa and Manisha Pai. Thank you guys for being here.
Thanks for having us. Absolutely.
Exciting times, never a dull moment for Vertex. We had an investor dinner last night. Vertex, of course, one of the most important talking points because you have so much going on, including PDUFA dates and all sorts of exciting things. Maybe the first opening question would be just tell us about the business as it stands today with the focus on the execution of CF and, of course, some of the pipeline. So maybe just give us an introduction to the most important milestones coming up for Vertex. I think most people know Vertex, but how you guys are feeling about the business right now and some of the most important milestones.
Sure. I'll try and do a quick tour.
Quick tour. Coming off very strong third quarter results, which we're pleased to see really nice balanced growth from CF in the U.S. and internationally, and good progress from our ongoing launches in products outside of CF, namely JOURNAVX and CASGEVY, which remain on track to contribute north of $500 million this year to our total $13 billion plus guidance in revenue for the year.
I think that during the quarter, you had some pretty good clinical milestones, including the AMPLIFIED results for inaxaplin in additional patient populations, and that's one of the key catalysts coming up. I'll go in sequential order to make things easy, if you will. The next key catalyst will be the November 30th PDUFA date for povetacicept in immunoglobulin A nephropathy. We are launch-ready. We've had our launch-ready meeting.
We're very excited, have had very good interactions with FDA, things remain on track, and are ready to go November 30th. That'll be the first launch in our new renal franchise, which is an exciting time for us given that we now have not only the CF franchise, but commercialized in sickle cell disease with CASGEVY, in acute pain with JOURNAVX, now in acromegaly with PALSONIFY post the Crinetics acquisition, which also had a good September result. Then we'll be excited to enter into our fifth area with IgAN as the first of four pipeline products in renal. November 30th is the PDUFA date. We also have promised before the end of the year results in myotonic dystrophy type 1. That'll be a phase II proof of concept study.
Obviously, a tough disease, lots happening out there, but happy to talk about that in more detail if you'd like. We said in the first quarter of 2027, you will get the interim analysis from the phase III study called AMPLITUDE for inaxaplin in APOL1-mediated kidney disease. We're really looking forward to that. If positive, that would put us on the path for accelerated approval in the U.S. In the first half of the year, you'll also get the results from the two phase III studies that are ongoing in diabetic peripheral neuropathy.
This would be the potential for the first indication in chronic pain to complement what we're doing in acute pain for JOURNAVX. I think those are some of the big key catalysts coming up, and I'm happy to jump into your specific- So much that I can't get through it in the next 25 minutes.
All right. We'll try and stay focused. In the near term, as you mentioned, November 30th PDUFA date. On the earnings call just a couple weeks ago, Vertex remains confident in the approval. I'm not exactly sure why there's even a debate, but maybe you could just speak to your confidence because on one side, people worry that the contract manufacturer specifically is a new contract manufacturer that is supporting the manufacturing of pove. On the other hand, the data results are obviously very strong. There's been multiple other recent approvals, so it should be a straightforward path. To what degree does Vertex have confidence in the overall contract manufacturing and the approval with that CMC company?
Sure. In any given six-month priority review, there is a set cadence of events, meetings with FDA, inspections, et cetera. We don't go into any of the specifics, but we have been confident in saying, and I'll repeat today, that everything has happened that should be happening.
We remain fully on track for November 30th. Without going into any of the specifics, things are looking good, and as I said, we're launch-ready and excited to go.
Fantastic. On one side, while you guys remain confident on that and everything remains on track, also the overall profile of the drug, including the fact about efficacy, safety, and convenience, I think are important aspects of pove versus your competitors. Meaning strong efficacy, arguably best in class.
Strong convenience, once-a-month pen. Auto-injector, yep.
Versus others, which are IV or weekly injections. So you have the best in class. On the other side, some investors worry about the overall safety profile because of the potential risk of hypogammaglobulinemia and the reduction of IgG. Can you speak to Vertex's view about the safety profile of the drug, phase III was presented recently, and whether or not the label or monitoring should be or would be any different than the other approvals?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
